A Multicenter Confirmatory Randomized-Controlled Study of rhNRGβ1 Protein Replacement Therapy in a Murine Model of NF2-related Schwannomatosis
Michael Reuter, Susann Groth, Johanna Schleep, Lars Björn Riecken, Lisa Schindler, Marie Juliane Jung, Venkat Krishnan Sundaram, Emilio Cirri, Nadine Pömpner, Lisa Wedekind, Julia Palm, André Scherag, Ruth Martha Stassart, Robert Fledrich, Reinhard Bauer, Helen Morrison
Across three German sites and 207 analyzed mice, systemic rhNRGβ1 at 10 µg/kg did not reduce schwannoma nerve thickness or shift Schwann cell differentiation markers.
bioRxiv · Aug 4, 2026 · PreprintCancer Biology✦ In-depth digest